Tri-Institutional Therapeutics Discovery Institute Inc
- Assets
- $8.0m
- Revenue
- $18.7m
- Investments
- $0.0
- Employees
- 37
- Location
- New York, NY
- Founding
- 08/2014
- Data as of
- 12/2023
- EIN
- 46-3673346
Organization Overview
Tri-Institutional Therapeutics Discovery Institute Inc is located in New York, NY. The organization was established in 2014. According to its NTEE Classification (H99) the organization is classified as: Medical Research N.E.C., under the broad grouping of Medical Research and related organizations. As of 12/2023, Tri-Institutional Therapeutics Discovery Institute Inc employed 37 individuals. This organization is an independent organization and not affiliated with a larger national or regional group of organizations. Tri-Institutional Therapeutics Discovery Institute Inc is a 501(c)(3) and as such, is described as a "Charitable or Religous organization or a private foundation" by the IRS.
For the year ending 12/2023, Tri-Institutional Therapeutics Discovery Institute Inc generated $18.7m in total revenue. The organization has seen a slow decline revenue. Over the past 6 years, revenues have fallen by an average of (1.2%) each year. All expenses for the organization totaled $18.7m during the year ending 12/2023. As we would expect to see with falling revenues, expenses have declined by (1.4%) per year over the past 6 years. You can explore the organizations financials more deeply in the financial statements section below.
Form
990
Mission & Program ActivityExcerpts From the 990 Filing
TAX YEAR
2023
Describe the Organization's Mission:
Part 3 - Line 1
THE SANDERS TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. WAS ORGANIZED AND IS OPERATED AS AN INDEPENDENT, NON-PROFIT CORPORATION, CONTROLLED BY LEADING NOT-FOR-PROFIT ACADEMIC, MEDICAL AND RESEARCH INSTITUTIONS, TO FURTHER AND IMPROVE HEALTH AND THE DIAGNOSIS, PREVENTION AND TREATMENT OF DISEASE THROUGH FUTHERING AND IMPROVING TRANSLATIONAL RESEARCH, GENERATE INNOVATIVE PROOF-OF-CONCEPT STUDIES, AND ADVANCE THE SCIENTIFIC ACTIVITIES OF THE CONTROLLING INSTITUTIONS' (MEMORIAL SLOAN KETTERING CANCER CENTER, THE ROCKEFELLER UNIVERSITY AND WEILL CORNELL MEDICAL COLLEGE)FACULTY, FELLOWS AND STUDENTS IN ASPECTS OF TRANSLATIONAL RESEARCH, CHEMISTRY, PHARMACOLOGY, AND DRUG DISCOVERY.
Describe the Organization's Program Activity:
Part 3 - Line 4a
THE SANDERS TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, A PARTNERSHIP AMONG THREE WORLD-RENOWNED SCIENTIFIC AND MEDICAL INSTITUTIONS, WORKS TO MORE EFFECTIVELY DEVELOP THERAPEUTICS THAT ARISE FROM DISCOVERIES MADE IN BASIC SCIENCE LABS. WITH A FOCUS ON EARLY-STAGE DRUG DISCOVERY, THE INSTITUTE PROVIDES EXPERTISE IN MEDICINAL CHEMISTRY AND COMPOUND SCREENING, AND CONDUCTS PROOF OF CONCEPT STUDIES NEEDED TO DEMONSTRATE THAT DRUG CANDIDATES CAN SUCCESSFULLY ALTER THE COURSE OF A DISEASE. SPECIFIC RESEARCH PROJECTS FOCUS ON ALZHEIMERS DISEASE, SICKLE CELL, OSTEOPOROSIS, LYSOSOMAL, LIPID DEPOSITS, PARKINSON'S AND BASAL CELL CARCINOMA.
THE INSTITUTE FACILITATES MORE EFFICIENT SHARING OF CORE FACILITIES BETWEEN THE THREE PARTNER INSTITUTIONS AND FORMS INDUSTRY PARTNERSHIPS WITH PHARMACEUTICAL AND BIOTECH COMPANIES TO FURTHER ADVANCE DRUG RESEARCH. IT SEEKS TO CREATE INTELLECTUAL PROPERTY THAT CAN BE FURTHER DEVELOPED BY AN OPEN FIELD OF INDUSTRY COLLABORATORS. THE MAJORITY OF SUCH SERVICES RELATE TO MEDICINAL CHEMISTRY SUPPORT.
Get More from Intellispect for FreeCreate a free account to get more data, nonprofit salaries, advanced search and more.
Board, Officers & Key Employees
| Name (title) | Role | Hours | Compensation |
|---|---|---|---|
Robert Harrington MD Effective 915 Member Of The Board Of Dir | Trustee | 0 | $0 |
Barry Coller MD Member Of The Board Of Dir | Trustee | 0 | $0 |
Richard P Lifton Mdphd Member Of The Board Of Dir | Trustee | 0 | $0 |
Carl Nathan MD Member Of The Board Of Dir | Trustee | 0 | $0 |
David Scheinberg MD PHD Member Of The Board Of Dir | Trustee | 0 | $0 |
Selwyn Vickers MD Member Of The Board Of Dir | Trustee | 0 | $0 |
Outside Vendors & Contractors
| Vendor Name (Service) | Service Year | Compensation |
|---|---|---|
Genscripts Professional Services | 12/30/23 | $330,895 |
Wuxi Professional Services | 12/30/23 | $2,421,400 |
Ablexis Llc Professional Services | 12/30/23 | $1,000,000 |
Hitgen Professional Services | 12/30/23 | $329,375 |
Single Cell Techmology Professional Services | 12/30/23 | $295,800 |
Financial Statements
| Statement of Revenue | |
|---|---|
| Federated campaigns | $0 |
| Membership dues | $0 |
| Fundraising events | $0 |
| Related organizations | $0 |
| Government grants | $0 |
| All other contributions, gifts, grants, and similar amounts not included above | $0 |
| Noncash contributions included in lines 1a–1f | $0 |
| Total Revenue from Contributions, Gifts, Grants & Similar | $0 |
| Total Program Service Revenue | $18,571,887 |
| Investment income | $131,317 |
| Tax Exempt Bond Proceeds | $0 |
| Royalties | $0 |
| Net Rental Income | $0 |
| Net Gain/Loss on Asset Sales | $0 |
| Net Income from Fundraising Events | $0 |
| Net Income from Gaming Activities | $0 |
| Net Income from Sales of Inventory | $0 |
| Miscellaneous Revenue | $0 |
| Total Revenue | $18,703,204 |
| Statement of Expenses | |
|---|---|
| Grants and other assistance to domestic organizations and domestic governments. | $0 |
| Grants and other assistance to domestic individuals. | $0 |
| Grants and other assistance to Foreign Orgs/Individuals | $0 |
| Benefits paid to or for members | $0 |
| Compensation of current officers, directors, key employees. | $597,153 |
| Compensation of current officers, directors, key employees. | $413,878 |
| Compensation to disqualified persons | $4,927,041 |
| Other salaries and wages | $0 |
| Pension plan accruals and contributions | $1,550,557 |
| Other employee benefits | $423,688 |
| Payroll taxes | $0 |
| Fees for services: Management | $0 |
| Fees for services: Legal | $130,252 |
| Fees for services: Accounting | $102,000 |
| Fees for services: Lobbying | $0 |
| Fees for services: Fundraising | $0 |
| Fees for services: Investment Management | $0 |
| Fees for services: Other | $6,510,805 |
| Advertising and promotion | $0 |
| Office expenses | $76,963 |
| Information technology | $743,353 |
| Royalties | $0 |
| Occupancy | $1,880,408 |
| Travel | $63,903 |
| Payments of travel or entertainment expenses for any federal, state, or local public officials | $0 |
| Conferences, conventions, and meetings | $0 |
| Interest | $0 |
| Payments to affiliates | $0 |
| Depreciation, depletion, and amortization | $378,458 |
| Insurance | $73,288 |
| All other expenses | $0 |
| Total functional expenses | $18,703,204 |
| Balance Sheet | |
|---|---|
| Cash—non-interest-bearing | $0 |
| Savings and temporary cash investments | $5,570,402 |
| Pledges and grants receivable | $0 |
| Accounts receivable, net | $0 |
| Loans from Officers, Directors, or Controlling Persons | $0 |
| Loans from Disqualified Persons | $0 |
| Notes and loans receivable | $0 |
| Inventories for sale or use | $0 |
| Prepaid expenses and deferred charges | $1,396,089 |
| Net Land, buildings, and equipment | $986,995 |
| Investments—publicly traded securities | $0 |
| Investments—other securities | $0 |
| Investments—program-related | $0 |
| Intangible assets | $0 |
| Other assets | $0 |
| Total assets | $7,953,486 |
| Accounts payable and accrued expenses | $0 |
| Grants payable | $0 |
| Deferred revenue | $5,420,818 |
| Tax-exempt bond liabilities | $0 |
| Escrow or custodial account liability | $0 |
| Loans and other payables to any current Officer, Director, or Controlling Person | $0 |
| Secured mortgages and notes payable | $0 |
| Unsecured mortgages and notes payable | $0 |
| Other liabilities | $2,532,668 |
| Total liabilities | $7,953,486 |
| Net assets without donor restrictions | $0 |
| Net assets with donor restrictions | $0 |
| Capital stock or trust principal, or current funds | $0 |
| Paid-in or capital surplus, or land, building, or equipment fund | $0 |
| Retained earnings, endowment, accumulated income, or other funds | $0 |
| Total liabilities and net assets/fund balances | $7,953,486 |